STI/HIV Hot Topics

Antibiotic resistant STIs such as gonorrhea and Mycoplasma genitalium are of increasing concern, however, health professionals may not be aware of new therapies and alternative regimens to address these infections. In 2025 two new oral therapies for gonorrhea were approved by the US FDA, which can be used in case of allergy to ceftriaxone. Additionally there have been additional studies from Australia (Htaik et al 2025) that describe alterative regimens for MG treatment failure. This session will inform providers about potential alternative therapies for antibiotic resistant STIs, as well as new developments in STI testing technology that will prepare them to accurately diagnose STIs and treat challenging cases. Additionally, there are now multiple oral and injectable regimens for HIV pre exposure prophylaxis, and a new biannual regimen, lenacapvir was recently recommended by the CDC for use in the US in the 2nd quarter of 2025. Given the regimen is so new, health care providers may not be aware of pros/cons of each regimen and how to deliver counseling messages. This session will discuss both oral and injectable PrEP regimens, including efficacy and side effects, so participants are prepared to counsel their patients on selection of biomedical HIV prevention medication.